How are energy investors positioned?
Additionally, Smith acquired 1,095 shares of common stock through the exercise of restricted stock units, which did not involve any cash transaction. The restricted stock units were part of a grant made on February 15, 2023, with a vesting schedule extending over three years. InvestingPro subscribers can access comprehensive insider trading analysis and 13 additional key insights about MacroGenics (NASDAQ:MGNX), including detailed financial health metrics and earnings forecasts. The company maintains a strong liquidity position with a current ratio of 3.75, though it faces profitability challenges. InvestingPro subscribers can access comprehensive insider trading analysis and 13 additional key insights about MacroGenics, including detailed financial health metrics and earnings forecasts. The company maintains a strong liquidity position with a current ratio of 3.75, though it faces profitability challenges.
Additionally, Smith acquired 1,095 shares of common stock through the exercise of restricted stock units, which did not involve any cash transaction. The restricted stock units were part of a grant made on February 15, 2023, with a vesting schedule extending over three years.
In other recent news, MacroGenics Inc. has announced a significant change in its financial leadership. Lynn Cilinski, who has served as the company’s Vice President, Controller, Treasurer, and Principal Accounting Officer, will be retiring effective January 2, 2025, after 21 years of service. Following her departure, Beth Smith will take over these roles. Smith has been with MacroGenics since 2013 and has served as Executive Director of Accounting and Assistant Controller since June 2022. She holds a Bachelor of Science in Accounting from Bucknell University and has worked in various roles of increasing responsibility within the company. The company has not yet entered into any material plans or contracts with Smith related to her new position, but it has stated that any such agreements will be disclosed in an amended report if established. This leadership transition highlights a strategic move within MacroGenics as it continues to evolve its management team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.